medigraphic.com

2023, Number 3

<< Back Next >>

Rev Mex Anest 2023; 46 (3)

Ketamine clinics: current uses based on evidence

Torres-Valdés SS, Carrillo-Torres O, Rascón-Martínez DM

Language: Spanish
References: 47
Page: 197-203
PDF size: 282.20 Kb.


ABSTRACT

Ketamine is a drug known for its benefits as an anesthetic inducer and to reduce the possibility of complications such as exacerbation of neuropathic pain and hyperalgesia associated with opioids. In this review we will focus on other indications in which it has also proven to be useful and that, under adequate observation and instruction in an infrastructure designed for it (ketamine clinics), improves the quality of behavior and decreases stress, anxiety and pain. Among the indications for its use are depressive disorders, anxiety disorder, obsessive-compulsive disorder and those related to emotional trauma; bipolar disorder, abnormalities in behavior and eating intake as well as addictive disorders.


REFERENCES

  1. Neira RF, Ortega GJL. La ketamina en el tratamiento del dolor crónico según medicina basada en la evidencia. Rev SocEsp Dolor. 2016;23:292-306.

  2. Chebini A, Marzoughi S, Randhawa J, Guh D, Wiseman S, Fedoroff I, et al. The effects of a multiday (10-14 days) subanesthetic dose IV ketamine infusion in the treatment of refractory chronic pain. Pain Manag. 2022;12:337-346.

  3. Kohtala S. Ketamine-50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol Rep. 2021;73:323-345.

  4. Cáñez-Jiménez C, González-López N, Ramírez-Segura EH. Ketamina: adyuvante en el tratamiento del dolor de difícil control. 7a Reunión Interinstitucional de Residentes de Anestesiología. Rev Mex Anest. 2018;41:S153-154.

  5. Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Vol. 43, Regional Anesthesia and Pain Medicine. Lippincott Williams and Wilkins; 2018. p. 521-546.

  6. Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. Ketamine Infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg. 2019;129:241-254.

  7. Johnstone-Petty M. Ketamine use for complex pain in the palliative care population. J Hosp Palliat Nurs. 2018;20:561-567.

  8. Yang Y, Maher DP, Cohen SP. Emerging concepts on the use of ketamine for chronic pain. Expert Rev Clin Pharmacol. 202013:135-146.

  9. Castillo PEA, Quesada ALM, Losada OCA, Cely ACA. Nuevas propuestas del uso de la ketamina en el manejo del trastorno afectivo bipolar (TAB) y del dolor Crónico. Neuronum. 2020;6:86-96.

  10. Veen C, Jacobs G, Philippens I, Vermetten E. Subanesthetic dose ketamine in posttraumatic stress disorder: a role for reconsolidation during trauma-focused psychotherapy? Curr Top Behav Neurosci. 2018;38:137-162.

  11. Mihaljevic S, Pavlovic M, Reiner K, Cacic M. Therapeutic Mechanisms of Ketamine. Psychiatr Danub. 2020;32:325-333.

  12. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al. A Consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74:399-405.

  13. Keeler JL, Treasure J, Juruena MF, Kan C, Himmerich H. Ketamine as a treatment for anorexia nervosa: a narrative review. Nutrients. 2022;14:2118.

  14. Ballard ED, Zarate CA. The role of dissociation in ketamine's antidepressant effects. Nat Commun. 2020;11:6431.

  15. Chen MH, Cheng CM, Gueorguieva R, Lin WC, Li CT, Hong CJ, et al. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study. Neuropsychopharmacology. 2019;44:2112-2118.

  16. Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and longer-term outcomes using ketamine as a clinical treatment at the yale psychiatric hospital. J Clin Psychiatry. 2018;79:17m11731.

  17. Sahib AK, Loureiro JR, Vasavada MM, Kubicki A, Wade B, Joshi SH, et al. Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression. Transl Psychiatry. 2020;10:260.

  18. Derakhshanian S, Zhou M, Rath A, Barlow R, Bertrand S, DeGraw C, et al. Role of Ketamine in the Treatment of Psychiatric Disorders. Health Psychol Res. 2021;9:25091.

  19. Gilbert JR, Galiano CS, Nugent AC, Zarate CA. Ketamine and attentional bias toward emotional faces: dynamic causal modeling of magnetoencephalographic connectivity in treatment-resistant depression. Front Psychiatry. 2021;12:673159.

  20. Kadriu B, Ballard ED, Henter ID, Murata S, Gerlus N, Zarate CA Jr. Neurobiological biomarkers of response to ketamine. Adv Pharmacol. 2020;89:195-235.

  21. Cathomas F, Bevilacqua L, Ramakrishnan A, Kronman H, Costi S, Schneider M, et al. Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression. Transl Psychiatry. 2022;12:12.

  22. Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012;72:e27-28.

  23. Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A, et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17:331-336.

  24. Niciu MJ, Iadarola ND, Banerjee D, Luckenbaugh DA, Park M, Lener M, et al. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. J Psychopharmacol. 2017;31:1570-1577.

  25. Park LT, Falodun TB, Zarate CA Jr. Ketamine for treatment-resistant mood disorders. Focus (Am Psychiatr Publ). 2019;17:8-12.

  26. Hirota K, Lambert DG. Ketamine and depression. Br J Anaesth. 2018;121:1198-1202.

  27. Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78:e852-e857.

  28. Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C, Cipriani A, Hawton K. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry. 2020;54:29-45.

  29. Kaiser P, San F, Mcinnes LA, Spesny SL, Radulovich Muñoz M. El papel de la ketamina como antidepresivo, un artículo de revisión. Revista Cúpula. 2017;31: 8-17.

  30. Alberich S, Martínez-Cengotitabengoa M, López P, Zorrilla I, Núñez N, Vieta E, González-Pinto A. Efficacy and safety of ketamine in bipolar depression: a systematic review. Rev Psiquiatr Salud Ment. 2017;10:104-112.

  31. Glue P, Medlicott NJ, Harland S, Neehoff S, Anderson-Fahey B, Le Nedelec M, et al. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017;31:1302-1305.

  32. Whittaker E, Dadabayev AR, Joshi SA, Glue P. Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Ther Adv Psychopharmacol. 2021;11:204512532110567.

  33. Dadabayev AR, Joshi SA, Reda MH, Lake T, Hausman MS, Domino E, Liberzon I. Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: a randomized double-blind clinical trial. Chronic Stress (Thousand Oaks). 2020;4:2470547020981670.

  34. Liriano F, Hatten C, Schwartz TL. Ketamine as treatment for post-traumatic stress disorder: a review. Drugs Context. 2019;8:212305.

  35. Feder A, Rutter SB, Schiller D, Charney DS. The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Adv Pharmacol. 2020;89:261-286

  36. American Psychiatric Association. Manual diagno?stico y estadi?stico de los trastornos mentales: DSM-5. Washington, DC, London, England, Editorial Me?dica Panamericana; 2014.

  37. Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021;178:193-202.

  38. Martinotti G, Chiappini S, Pettorruso M, Mosca A, Miuli A, Di Carlo F, et al. Therapeutic potentials of ketamine and esketamine in obsessive-compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature. Brain Sci. 2021;11(7):856.

  39. Sharma LP, Thamby A, Balachander S, Janardhanan CN, Jaisoorya TS, Arumugham SS, et al. Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. Asian J Psychiatr. 2020;52:102183.

  40. Vega-Dienstmaier JM. Avances en el tratamiento farmacológico del trastorno obsesivo-compulsivo. Rev Neuropsiquiatr. 2016;79:239-246.

  41. Truppman Lattie D, Nehoff H, Neehoff S, Gray A, Glue P. Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. J Psychopharmacol. 2021;35:137-141.

  42. Glue P, Neehoff SM, Medlicott NJ, Gray A, Kibby G, McNaughton N. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018;32:663-667.

  43. Zarate CA. Ketamine: a new chapter in antidepressant development. Braz J Psychiatry. 2020;42:581-582.

  44. Scolnick B, Zupec-Kania B, Calabrese L, Aoki C, Hildebrandt T. Remission from chronic anorexia nervosa with ketogenic diet and ketamine: case report. Front Psychiatry. 2020;11:763.

  45. Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry. 2018;9:277.

  46. Worrell SD, Gould TJ. Therapeutic potential of ketamine for alcohol use disorder. Neurosci Biobehav Rev. 2021;126:573-589.

  47. Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177:125-133.




2020     |     www.medigraphic.com